Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback